Figure 2: Pharmacokinetics of TFV in BALB/c and BLT mice. | Scientific Reports

Figure 2: Pharmacokinetics of TFV in BALB/c and BLT mice.

From: Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model

Figure 2

(a) BALB/c (n = 8) and BLT (n = 8) mice were administered a single dose of 300 mg/kg TDF and the concentrations of TFV (plasma, CVL, and the FRT) and TFVdp (FRT) measured 24 h later. The concentration of TFV present in (b) plasma, (c) CVL, and (d) the FRT of BALB/c and BLT mice. (e) The concentration of TFVdp in the FRT of BALB/c and BLT mice. (b–e) Shown are the median TFV and TFVdp concentrations (horizontal line) and interquartile range (vertical lines). An exact Mann-Whitney test was used to compare the concentrations of TFV and TFVdp between BALB/c and BLT mice (*p < 0.05, **p < 0.01). Mouse vector art authored by Gwilz (https://commons.wikimedia.org/wiki/File%3AVector_diagram_of_laboratory_mouse_(black_and_white).svg).

Back to article page